Safety and Effectiveness of Orbera365™ Intragastric Balloon System

The study's objective is to confirm the safety of the Orbera365™ Intragastric Balloon (IGB) for extended in situ dwell time (from 6 months up to 12 months). This information can be collected from standard-of-care data. Up to ten (10) sites located in Europe are planned to participate in this registry. A minimum of 100 subjects are required for the registry. A maximum of 200 subjects may be enrolled into the registry.

The study population will include Obese patients ((Body Mass Index (BMI) 30-50 kg/m2)) who have already consented to receive the Orbera365™ IGB System, who previously failed to achieve and maintain weight loss with a supervised weight-control program.

Study subjects will also include obese and super obese patients (BMI 40 kg/m2 and above or a BMI of 35 kg/m2 with comorbidities) prior to obesity or other surgery, in order to reduce surgical risk.

The duration of study participation is expected to be up to thirteen months from study placement procedure. The total treatment with the study device will be no more than 12 months from placement. A 30-day post-removal assessment will be performed following the study removal procedure. The subject will have completed the study upon the completion of the 30-day post-removal assessment, regardless of when the study removal procedure occurred.

Inclusion criteria

• Subject is ≥ 18 years of age
• Subject meets the indicated population for the device according to the Instructions for Use (IFU) including obese patients with the BMI of 30-50 kg/m2 for weight loss and patients with BMI 40 kg/m2 and above or a BMI of 35 kg/m2 with comorbidities before obesity or another surgery, unless contraindicated.
• Subject is able to read, understand, and sign a written Informed Consent Form to participate in the registry

Exclusion criteria

• Subject is planning on becoming pregnant during the one year following study device placement
• Subject will complete follow-up visits at a location that the treating physician does not practice
• Subjects who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
• Current use or use within the three months before the baseline visit of over-the-counter or prescribed weight loss supplements/medications.
• Subjects who have conditions that are contraindicated for Orbera365™ IGB System as per the IFU, including, but not limited to:

• The presence of more than one IGB at the same time.
• Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease
• Potential upper gastrointestinal bleeding conditions
• A large hiatal hernia of > 5cm or a hernia ≤ 5 cm associated with severe or intractable gastro- esophageal reflux symptoms
• A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope
• Achalasia, symptoms suggestive of delayed gastric emptying, or presence of any other severe motility disorder that that may pose a safety risk during placement or removal of the device.
• Gastric Mass.
• Severe coagulopathy.
• Taking aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants and not under medical supervision.
• Prior surgery involving the esophagus, stomach, and duodenum or bariatric surgery